卵巢癌术前新辅助化疗筛选与评估的展望

doi:10.11904/j.issn.1002-3070.2014.06.015

实用肿瘤学杂志 ›› 2014, Vol. 28 ›› Issue (6): 553-556.doi: 10.11904/j.issn.1002-3070.2014.06.015

卵巢癌术前新辅助化疗筛选与评估的展望

宋雨霖综述, 王晶审校

哈尔滨医科大学附属肿瘤医院妇三科(哈尔滨 150081)

收稿日期:2014-06-25 出版日期:2014-12-28 发布日期:2015-01-08
通讯作者: 王晶,E-mail:wj6507@163.com
作者简介:宋雨霖,女,(1988-),硕士研究生,从事妇科肿瘤临床的研究

The screening and assessment of the neoadjuvant chemotherapy for the ovarian cancer

SONG Yulin,WANG Jing

Department of Gynaecology,The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081,China

Received:2014-06-25 Online:2014-12-28 Published:2015-01-08

摘要/Abstract

摘要：

卵巢癌是妇科恶性肿瘤致死率最高的肿瘤。肿瘤细胞减灭术辅以术后铂类为主的联合化疗是目前公认的卵巢癌标准治疗方案。但对于就诊时已属晚期且伴发高危疾病,无法直接手术的患者,术前的新辅助化疗(Neoadjuvant chemotherapy,NACT)的应用显示出了优越性,并得到了临床医生的肯定且已应用于晚期恶性肿瘤的治疗中。值得探讨的是:哪些患者在初次治疗时宜选用新辅助化疗,而不是直接行肿瘤细胞减灭术。本文对近年来的相关研究进行了归纳总结,希望对临床医生的决策有所帮助。

关键词: 晚期卵巢癌, 新辅助化疗, 评估, 筛选标准

Abstract:

Ovarian cancer is the highest death rate of gynecologic malignant tumor.Currently,people recognize standard treatment for ovarian cancer was that reduction-Tumor cells of platinum based chemotherapy after surgery.But for those patients who have developed into advanced cancer that cannot be operated the surgeries directly,the application of preoperative Neoadjuvant chemotherapy(NACT)does have the superiority.which is recognized by the majority of clinical doctors,and has been widely used in the treatment of advanced malignant tumor.It is worthy to discussing which part of patients should choose the initial treatment of Neoadjuvant chemotherapy,rather than a direct treatment of destroying tumor cells.This article is summarizing the empirical cases based on related research,in order to help clinicians to make a decision on the treatment of ovarian cancer.

Key words: Advanced ovarian cancer, Neoadjuvant chemotherapy, Assessment, Screening criteria

中图分类号:

R730.53

宋雨霖综述, 王晶审校. 卵巢癌术前新辅助化疗筛选与评估的展望[J]. 实用肿瘤学杂志, 2014, 28(6): 553-556.

SONG Yulin,WANG Jing. The screening and assessment of the neoadjuvant chemotherapy for the ovarian cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 553-556.

参考文献

1 Stuart GCE,Kitchener H,Bacon M,et al.2010 Gynecologic Cancer Inter Group(GCIG)consensus statement on clinical trials in ovarian cancer.Report from the fourth ovarian cancer consensus conference[J].Gynecol Cancer,2011,21(3):750-755.
2 Vergote I,Trope CG,Amant F,et al.Neoadjuvant chemotherapy or primary surgery in stage IIIc-IV ovarian cancer[J].New Engl Med,2010,363(9):943-953.
3 Vergot IB,De Wever I,Decloedt J,et al.Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer[J].Semin Oncol,2000,27(1):31-36.
4 Hou JY,Kelly MG,Yu H,et al.neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease[J].Gynecologic Oncology,2007,105(1);211-217.
5 Petria L,Hogdall E,Christensen IJ,et al.Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer[J].APUIS,2006,114(5):359-363.
6 Brockbank EC,Ind TE,Barton DP,et al.Preoperative predictors of suboptimal primary surgical cytoreduction in patients with advanced ovarian carcinoma[J].Int J Gynecol Cancer,2004,14(1):42-50.
7 祝绚,甘晓琴,陈曼,等.血清肿瘤标志物检测在盆腔良恶性妇科肿瘤诊断与鉴别诊断中的意义[J].检验医学与临床,2013,10(17):2231-2232.
8 沈伟春.联检CA125、CA153、AFP和CEA在卵巢癌中的诊断价值[J].现代诊断与治疗,2013,24(14):3620-3621.
9 朱强,吉川裕幸,藤田信行,等.CT和核磁成像在原发性卵巢癌分期中的应用[J].中华肿瘤杂志,1999,21(4):296-299.
10 Dowdy SC,Mullany SA,Brandt KR,et al.The utility of computed to mography seans in predicting suboptimal cytoreductive surgery in women with adwanced ovarian carcinoma[J].Cancer,2004,101(2):346-352.
11 Qayyum A,Coakley FV,Westphalen AC,et al.Role of CT and MRI imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer[J].Gynecol Oncol,2005,96(2):301-306.
12 顾欣,娄阁,张嘉文,等.¹⁸FDG-PET诊断卵巢癌治疗后复发的价值[J].实用肿瘤学杂志,2007,21(3):270-272.
13 吴明秀.PET-CT在妇科恶性肿瘤的应用[J].中国医疗前沿,2013,8(6):87-88.
14 朱剑锋,邱刚,朱静红,等.PET-CT在诊断卵巢癌中的应用价值[J].中国医药指南,2013,11(21):194-195.
15 Fagotti A,Fanfani F,Ludovisi M,et al.Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer:a pilot study[J].Gynecol Oncol,2005,96(3):729-735.
16 Chi DS,Mus AF,Dao F,et al.An analysis of patients with bulky advanced stage ovarian,tubal,and peritoneal carcinoma treated with primary debulking surgery(PDS)during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy(NACT)[J].Gynecol Oncol,2012,124(1):10-14.
17 黄琳娟,孔北华,何丽.晚期卵巢癌新辅助化疗的Meta分析[J].现代妇产科进展,2013,22(1):28-31.

[1]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[2]	陈力, 张玉新, 左艳娇, 马菲, 宋洪江, 薛英威. SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效比较[J]. 实用肿瘤学杂志, 2017, 31(1): 23-30.
[3]	戴猛, 李锐, 刘贵庭, 梁金龙, 冯金发, 徐善勇. 新辅助化疗后保留乳房手术治疗进展期乳腺癌可行性分析[J]. 实用肿瘤学杂志, 2016, 30(2): 109-113.
[4]	巴志昌, 王欣欣, 崔万辉, 国飞, 张修石. MRI弥散加权成像对宫颈癌新辅助化疗评估的应用价值[J]. 实用肿瘤学杂志, 2015, 29(6): 518-522.
[5]	于迎迎(综述),李晓霞(审校). PET/CT在滤泡淋巴瘤中的研究进展[J]. 实用肿瘤学杂志, 2015, 29(2): 140-143.
[6]	李嘉琪, 罗红雨, 栾瑾微, 李洋, 李香兰. 癌性营养不良在放疗中的研究进展[J]. 实用肿瘤学杂志, 2015, 29(1): 93-96.
[7]	朱宏, 朱莉, 韩世愈, 方芳, 于洋. 磁共振弥散加权成像对宫颈癌新辅助化疗后无进展生存期的预测价值[J]. 实用肿瘤学杂志, 2014, 28(6): 519-523.
[8]	宁四清, 詹波涛, 徐海声. TNP方案在头颈部鳞状细胞癌中的疗效探讨[J]. 实用肿瘤学杂志, 2014, 28(6): 540-544.
[9]	耿淑美, 赵素彦, 张晓伟, 马旭东, 董静, 贾喜花. 检测腹水中血管内皮生长因子对晚期卵巢癌维持治疗的临床意义[J]. 实用肿瘤学杂志, 2012, 26(5): 443-448.
[10]	马荣, 陈曦海, 耿晓星, 刘爽, 张恒. 术前同期放化疗对局部晚期宫颈癌近期疗效的综合评价[J]. 实用肿瘤学杂志, 2012, 26(4): 314-318.
[11]	滕冲, 宋晓薇, 蔡莉. Ki-67在乳腺癌新辅助化疗中的作用及临床意义[J]. 实用肿瘤学杂志, 2012, 26(2): 188-192.
[12]	刘扬, 庞达. 乳腺癌新辅助化疗前后Ki-67、HER-2、ER和PR的变化与临床缓解率的关系[J]. 实用肿瘤学杂志, 2011, 25(5): 442-445.
[13]	张一君, 邹天宁, 陈杨萍, 陈艳. 乳腺癌新辅助化疗疗效评价及预测的研究进展[J]. 实用肿瘤学杂志, 2011, 25(5): 477-481.
[14]	印明柱, 娄阁, 陈秀玮, 顾泰华. 新辅助化疗后根治性手术与同步放化疗在局部晚期宫颈癌的远期疗效评价^△[J]. 实用肿瘤学杂志, 2011, 25(1): 40-45.
[15]	张斌. 乳腺癌新辅助化疗应该注意的几个问题[J]. 实用肿瘤学杂志, 2010, 24(6): 502-505.

卵巢癌术前新辅助化疗筛选与评估的展望

The screening and assessment of the neoadjuvant chemotherapy for the ovarian cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价